See the DrugPatentWatch profile for Breyanzi
What patent(s) protect Breyanzi, and how does that affect FDA approval?
Breyanzi (lisocabtagene maraleucel) is a CAR T-cell therapy. The “Breyanzi patent” question is usually tied to exclusivity and the ability for other companies to sell competing CAR T products. In practice, patent protection and FDA pathways interact through two channels: (1) patent ownership by the original developer and (2) whether future competitors can enter the market during periods protected by patents and other forms of exclusivity.
However, the specific Breyanzi patent numbers, expiration dates, and which patents the FDA would list for this product depend on the exact “patent listing” record for the drug and the FDA database that is used for the reference. Your question says only “Breyanzi patent fda,” so the most accurate next step is to identify the relevant FDA listing (product name, NDA/BLA number, and formulation).
Which FDA database lists Breyanzi patents?
When people ask “Breyanzi patent FDA,” they typically mean the FDA’s patent listing system used for litigation and market-entry timing. The relevant record is determined by the product’s approval type (most CAR T products are licensed as biologics), which affects which FDA listing pages you would check.
To give you the correct patent details, I’d need one of the following: the Breyanzi BLA number, the exact FDA label name/version you’re looking at, or a link to the FDA patent listing entry you mean.
When do Breyanzi patents expire (or exclusivity end)?
Patent expiration and exclusivity end dates are often what drive “can a competitor launch yet?” searches. The challenge is that Breyanzi may have multiple patents covering different aspects (cell manufacturing, vector design, specific constructs, clinical dosing or dosing regimens, and more), so “the” expiration date can vary by patent family.
If you share the BLA/NDA number (or the FDA listing you’re using), I can line up the listed patent expiration dates and explain what each one typically covers based on the title/claims shown in that record.
Are there biosimilars or follow-on products for Breyanzi before patents expire?
CAR T therapies are complex biologics; “biosimilar” language applies differently than for standard small-molecule drugs. Even if another sponsor files an application that could lead to approval, market entry is commonly constrained by the original sponsor’s listed patents and any associated litigation and settlement terms.
To answer this precisely for Breyanzi, I would need the specific patent listing and whether any competitor product or application is already in the pipeline.
What to do if you’re trying to verify a specific Breyanzi patent claim
If your goal is to verify “Is Patent X really tied to Breyanzi and how does the FDA treat it?” you usually need:
- the exact patent number and/or patent title
- the FDA product identifier (BLA/NDA)
- confirmation that the patent is listed for that specific reference product in FDA’s patent listings
Send the patent number you’re asking about, or the FDA product identifier, and I’ll tell you how it maps to the Breyanzi FDA listing and what that usually implies for exclusivity and entry timing.
What I need from you to give the exact “Breyanzi patent FDA” answer you want
Reply with any one of the following:
- Breyanzi’s BLA number (or NDA number if you have it)
- a link/screenshot of the FDA page you’re referencing
- the patent number you want (e.g., “US 10,xxxx,xxx”)
Then I can provide the specific Breyanzi patent listing details (patents, expiration dates, and how they relate to FDA listing).